Abstract: Embodiments are directed to stateless communication using a stateful protocol. One or more NTMAs may establish a connection with a client computer based on data exchanged with a the client computer using the stateful protocol. The exchanged data may include validation information provided by the one or more NTMAs. The exchanged data and other information associated with the connection may be discarded from one or more memories of the one or more NTMAs. A network packet communicated over the network using the stateful protocol may be obtained. Verification information and candidate validation information may be generated based on one or more characteristics of the network packet. The network packet may be validated based on a comparison of the verification information and the candidate validation information. A reply that adheres to the stateful protocol may be provided to the client computer based on the validated network packet.

Abstract: Embodiments are directed to stateless communication using a stateful protocol. One or more NTMAs may establish a connection with a client computer based on data exchanged with a the client computer using the stateful protocol. The exchanged data may include validation information provided by the one or more NTMAs. The exchanged data and other information associated with the connection may be discarded from one or more memories of the one or more NTMAs. A network packet communicated over the network using the stateful protocol may be obtained. Verification information and candidate validation information may be generated based on one or more characteristics of the network packet. The network packet may be validated based on a comparison of the verification information and the candidate validation information. A reply that adheres to the stateful protocol may be provided to the client computer based on the validated network packet.

Abstract: Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

Abstract: The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.

Abstract: This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11 CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines.

Abstract: The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use.

Abstract: Biaryl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such biaryl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

Abstract: Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.